Brokers Issue Forecasts for ViewRay Inc.’s FY2016 Earnings (VRAY)
ViewRay Inc. (NASDAQ:VRAY) – Zacks Investment Research raised their FY2016 EPS estimates for shares of ViewRay in a research report issued on Tuesday. Zacks Investment Research analyst A. Dushyanth now forecasts that the firm will post earnings of ($1.35) per share for the year, up from their previous estimate of ($1.77). Zacks Investment Research also issued estimates for ViewRay’s Q4 2016 earnings at ($0.33) EPS, FY2017 earnings at ($0.88) EPS, FY2019 earnings at ($0.13) EPS and FY2020 earnings at $0.17 EPS.
ViewRay (NASDAQ:VRAY) last issued its quarterly earnings results on Monday, November 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by $0.08.
Separately, BTIG Research started coverage on shares of ViewRay in a research report on Wednesday, September 14th. They set a “buy” rating and a $6.00 price target for the company.
Shares of ViewRay (NASDAQ:VRAY) traded down 3.03% on Friday, reaching $3.20. 14,541 shares of the company’s stock were exchanged. ViewRay has a one year low of $2.64 and a one year high of $8.00. The firm has a 50 day moving average of $3.52 and a 200 day moving average of $3.96. The firm’s market capitalization is $122.87 million.
In other ViewRay news, Director Aditya Puri acquired 1,472,803 shares of the stock in a transaction dated Friday, September 9th. The stock was acquired at an average price of $2.95 per share, with a total value of $4,344,768.85. Following the completion of the purchase, the director now owns 18,964 shares in the company, valued at approximately $55,943.80. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David P. Bonita acquired 1,138,074 shares of the stock in a transaction dated Monday, August 22nd. The stock was acquired at an average cost of $2.95 per share, with a total value of $3,357,318.30. The disclosure for this purchase can be found here. 59.10% of the stock is currently owned by insiders.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Stock Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related stocks with our FREE daily email newsletter.